NASDAQ OMX (NDAQ) Adds 10 Stocks to NASDAQ Biotechnology Index (NBI)
Tweet
Share
E-mailGet Alerts NDAQ Hot Sheet
Join SI Premium – FREE
The NASDAQ OMX Group, Inc. (Nasdaq: NDAQ) says the results of the semi-annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, May 21, 2012.
The following ten securities will be added to the Index: Cerus Corporation (Nasdaq: CERS), Celldex Therapeutics, Inc. (Nasdaq: CLDX), Amicus Therapeutics, Inc.(Nasdaq: FOLD), Infinity Pharmaceuticals, Inc. (Nasdaq: INFI), Jazz Pharmaceuticals plc (Nasdaq: JAZZ), Omeros Corporation (Nasdaq: OMER), Orexigen Therapeutics, Inc. (Nasdaq: OREX), Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), Raptor Pharmaceutical Corp. (Nasdaq: RPTP) and Trius Therapeutics, Inc. (Nasdaq: TSRX).
The following ten securities will be added to the Index: Cerus Corporation (Nasdaq: CERS), Celldex Therapeutics, Inc. (Nasdaq: CLDX), Amicus Therapeutics, Inc.(Nasdaq: FOLD), Infinity Pharmaceuticals, Inc. (Nasdaq: INFI), Jazz Pharmaceuticals plc (Nasdaq: JAZZ), Omeros Corporation (Nasdaq: OMER), Orexigen Therapeutics, Inc. (Nasdaq: OREX), Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), Raptor Pharmaceutical Corp. (Nasdaq: RPTP) and Trius Therapeutics, Inc. (Nasdaq: TSRX).
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Getty Realty discloses separation terms for departing accounting officer
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- Holcim to acquire Fermacell from James Hardie for EUR 840M
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
